📈 Live Market Tracking
Every NSE and BSE corporate filing, read and explained by AI within minutes — impact, key figures, short/long-term view and what to watch.
Live · AI analyzer runs every 5 min (07:00–23:55 IST)
Latest filing: 2026-08-17 19:37
343 analysed today
343
Today
133,232
All-time analysed
40,094
Positive
6,279
Negative
79,048
Neutral
7,743
Watch
📊 Last 7 days — analysed filings by sentiment
Note: These are AI-generated, educational summaries of public NSE
filings — grounded in each document, but not investment advice and possibly incomplete.
Verify against the original filing and consult a SEBI-registered adviser before acting.
18 announcements match the current filters (relevance ≥ 5).
Q1 FY27 Healthcare Revenue Surges 85% to ₹142 Cr; Pen Capacity Expanding to 75M/Year
Shaily Engineering Plastics released its Q1 FY27 earnings call transcript, highlighting a 14% YoY increase in consolidated revenue to ₹281 crore and an 18% YoY rise in EBITDA to ₹83 crore (29.7% margin). Growth was driven by the Healthcare division, which jumped 85% YoY to ₹142 crore and now accounts for 51% of total revenue. The company is set to commission an additional 25 million pen capacity by September 2026, expanding total annual pen capacity to approximately 75 million pens. Meanwhile, the Consumer segment fell 24% YoY to ₹116 crore due to sluggish export demand in the US and Europe.
Confidence: HIGH
What changedShaily published its Q1 FY27 earnings call transcript detailing segment performance, new pen platform launches, and global expansion updates.
Why it mattersHealthcare has officially become Shaily's largest revenue contributor (51%), structurally lifting company EBITDA margins towards ~30% despite persistent export weakness in the consumer segment.
Consolidated Q1 Revenue: ₹281 croreHealthcare Segment Revenue: ₹142 croreHealthcare YoY Growth: 85%EBITDA Margin: 29.7%Total Pen Injector Capacity Post-Expansion: ~75 million pens/year
📅 Short termFocus remains on the seamless commissioning of the 25M pen line by September 2026 and dispatch ramp-ups for generic Semaglutide orders in Canada and Brazil.
📈 Long termTransition toward high-margin, IP-led drug delivery devices (emergency auto-injectors and on-body injectors) and the Abu Dhabi facility by FY28 positions Shaily for durable long-term margin expansion.
⚠ Risk flags
- Consumer segment slowdown (revenue down 24% YoY) due to US/Europe demand softness.
- Pharma regulatory approval timelines and customer concentration in drug delivery platforms.
Key Highlights
Healthcare revenue grew 85% YoY to ₹142 crore, contributing 51% of consolidated Q1 FY27 revenue.
Consolidated revenue stood at ₹281 crore (+14% YoY) with PAT rising 17% YoY to ₹48 crore (PAT margin of 17.1%).
Additional 25 million pen injector capacity on track for operationalization by end of September 2026, reaching ~75 million pens per annum.
Consumer segment revenue dropped 24% YoY to ₹116 crore amid soft demand in home furnishings in the US and Europe.
Targeting completion of emergency auto-injector program by end-FY27 and Abu Dhabi plant production by end-FY28.
👀 What to Watch
Track the commercialization and ramp-up of the additional 25 million pen capacity by end-September 2026 and potential partnership announcements with global pharmaceutical majors.
Shaily Re-appoints MD for 5-Year Term; Sets Sept 11 as Record Date for Final Dividend
Shaily Engineering Plastics has approved the re-appointment of Mr. Amit Mahendra Sanghvi as Managing Director for a five-year term effective October 1, 2026. The board also fixed September 11, 2026, as the record date for the final dividend of FY 2025-26. These decisions come alongside the approval of Q1 FY27 financial results. With a TTM revenue of ₹977 Cr and a strong ROCE of 30%, leadership continuity is vital for the company's stated 36% growth target driven by the healthcare segment.
Confidence: HIGH
What changedThe company has formalized the extension of its current Managing Director's tenure and established the timeline for its final dividend payment.
Why it mattersLeadership stability is critical as Shaily executes its strategy to scale IP-led healthcare platforms, which saw 171% growth in H1 FY26 and carries higher margins.
MD Re-appointment Term: 5 yearsDividend Record Date: 11th September 2026TTM Revenue: ₹977 CrTTM PAT: ₹168 CrROCE: 30.0%
📅 Short termThe stock may see routine activity around the dividend record date; management continuity is generally viewed as a non-event by the market if expected.
📈 Long termEnsures consistent execution of the long-term shift toward high-margin healthcare and drug delivery devices, which is central to the company's valuation re-rating.
⚠ Risk flags
- High customer concentration with large MNC clients
- Regulatory delays in pharma segment impacting dispatches
Key Highlights
Re-appointment of Amit Mahendra Sanghvi as MD for a 5-year term until September 30, 2031
Fixed September 11, 2026, as the Record Date for the FY 2025-26 final dividend
Board meeting concluded after 3 hours and 5 minutes of deliberation on August 8, 2026
Company maintains a high Operating Profit Margin (OPM) of 28.4% as per TTM data
Promoter holding remains stable at approximately 41.1% as of June 2026
👀 What to Watch
Investors should look for the formal approval of the MD's re-appointment and the final dividend at the upcoming 46th Annual General Meeting.
85% Healthcare Revenue Growth Drives Shaily's Q1 FY27 PAT up 17% to ₹48 Cr
Shaily Engineering Plastics reported a 14% YoY revenue growth to ₹280.7 Cr for Q1 FY27, primarily driven by a massive 85% surge in the Healthcare segment (₹142.4 Cr). Despite a 24% decline in the Consumer business due to weak demand in Western markets, consolidated EBITDA margins improved by 120 bps to 29.7%. Net profit rose 17% YoY to ₹48.0 Cr. The company secured new projects across FMCG, LED, and Automotive sectors, and received key approvals for Semaglutide pens in Canada and Brazil.
Confidence: HIGH
What changedThe revenue mix has structurally shifted toward the high-margin Healthcare segment, which now outweighs the Consumer segment for the first time.
Why it mattersHealthcare contracts are typically stickier and higher margin; the successful approval of Semaglutide pens in new markets validates Shaily's transition into a specialized medical device manufacturer.
Q1 FY27 Revenue: ₹280.7 CrHealthcare Revenue Growth: 85% YoYEBITDA Margin: 29.7%Debt to Equity Ratio: 0.2xHealthcare vs TTM Revenue: ~14.6%
📅 Short termThe market is likely to react positively to the strong margin expansion and the rapid scaling of the healthcare business despite consumer segment headwinds.
📈 Long termThe shift toward IP-led healthcare platforms and drug delivery devices (like Semaglutide) provides a high-margin, scalable growth runway over the next 3-5 years.
⚠ Risk flags
🔬 Flagged for deeper Multibagger analysis — view briefs →
- High customer concentration in the consumer segment
- Weak demand in Western markets for home furnishings
- Regulatory risks associated with pharma dispatches
Key Highlights
Healthcare segment revenue grew 85% YoY to ₹142.4 Cr, now contributing over 50% of total revenue.
Consolidated EBITDA margins expanded to 29.7% from 28.5% in the previous year's quarter.
Consumer business revenue declined 24% YoY to ₹115.5 Cr due to weak home furnishing demand in Europe and USA.
Annualized ROCE improved to 39.0% as of June 2026 compared to 35.8% in March 2026.
Received customer approvals for Semaglutide pens in Canada and Brazil, with two new IP-led platform projects signed.
👀 What to Watch
Monitor the commercialization timeline of the new IP-led healthcare platforms and the recovery of demand in the export-heavy consumer segment.
Shaily Engineering sets Sep 11 as Record Date for Dividend; MD re-appointed for 5 years
Shaily Engineering Plastics has fixed September 11, 2026, as the record date for its final dividend for FY 2025-26. The board also approved the re-appointment of Mr. Amit Mahendra Sanghvi as Managing Director for a five-year term effective October 1, 2026. These decisions follow a strong financial performance in FY26, where the company reported a PAT of ₹168 Cr, an 80% increase over FY25. The company continues to focus on its high-margin healthcare segment, which has been a primary growth driver.
Confidence: HIGH
What changedThe company has established the timeline for its final dividend payout and secured leadership continuity for the next five years through the MD's re-appointment.
Why it mattersLeadership stability is vital as Shaily transitions toward an IP-led healthcare model. The dividend record date is a routine but necessary administrative step for shareholder returns.
Record Date: 11-Sep-2026MD Tenure Extension: 5 yearsTTM PAT: ₹168 CrPromoter Holding: 41.09%TTM Revenue: ₹977 Cr
📅 Short termThe stock may see routine price adjustments around the ex-dividend date near September 11. The market is likely to focus more on the Q1 FY27 earnings performance approved in the same meeting.
📈 Long termThe re-appointment of the MD ensures strategic continuity for the company's shift into high-margin drug delivery devices, which has already improved gross margins by 1,230 bps.
⚠ Risk flags
- High customer concentration in the healthcare segment
- Recent decline in promoter holding from 43.39% to 41.09%
- High P/E ratio of 86.4 leaves little room for earnings misses
Key Highlights
Record date for final dividend for FY 2025-26 fixed as September 11, 2026
Managing Director Amit Mahendra Sanghvi re-appointed for a 5-year term until September 30, 2031
Board approved unaudited standalone and consolidated financial results for Q1 FY27
Promoter holding stands at 41.09% as of June 2026, down from 43.39% in March 2026
Company maintains a high OPM of 28.4% and ROCE of 30.0% based on TTM data
👀 What to Watch
Investors should track the upcoming Annual General Meeting (AGM) for the formal approval of the dividend amount and the MD's re-appointment. Monitor the execution of the healthcare segment expansion, which is critical for maintaining the current high valuation (P/E of 86.4).
16.7% YoY Profit Growth in Q1 FY27; MD Re-appointed for 5-Year Term
Shaily Engineering Plastics reported a steady Q1 FY27 with consolidated revenue growing 22.1% YoY to ₹274.78 cr. Consolidated net profit increased by 16.7% YoY to ₹48.01 cr, supported by strong standalone performance where PBT rose to ₹70.40 cr. The board confirmed the re-appointment of Managing Director Amit Sanghvi for a five-year term (2026-2031) and set September 11, 2026, as the record date for the final dividend.
Confidence: HIGH
What changedThe company reported its first-quarter results for FY27 showing continued growth and secured leadership continuity by re-appointing the Managing Director.
Why it mattersThe steady growth in revenue and profit validates Shaily's strategic shift toward high-margin healthcare and drug delivery devices. Leadership continuity is vital as the company executes its design-to-manufacture contracts with global MNCs.
Consolidated Revenue (Q1 FY27): ₹274.78 crConsolidated Net Profit (Q1 FY27): ₹48.01 crYoY Revenue Growth: 22.1%YoY Net Profit Growth: 16.7%Dividend Record Date: September 11, 2026
📅 Short termThe results are likely to be viewed positively by the market as they demonstrate consistent growth and operational stability. The announcement of the dividend record date provides a clear timeline for yield-seeking investors.
📈 Long termThe company's focus on IP-led platforms and expansion into the Middle East for drug delivery devices remains a structural growth driver, though high customer concentration remains a factor to watch.
⚠ Risk flags
- High customer concentration with large MNC clients
- Potential regulatory delays in pharma dispatches
Key Highlights
Consolidated revenue from operations rose to ₹274.78 cr in Q1 FY27 from ₹225.10 cr in Q1 FY26.
Consolidated net profit grew to ₹48.01 cr, up from ₹41.12 cr in the corresponding quarter last year.
Standalone Profit Before Tax (PBT) showed significant strength at ₹70.40 cr vs ₹48.25 cr YoY.
Managing Director Amit Mahendra Sanghvi re-appointed for a 5-year term effective October 1, 2026.
Record date for final dividend for FY 2025-26 fixed as Friday, September 11, 2026.
👀 What to Watch
Investors should monitor the continued margin expansion in the healthcare segment and the commercialization timeline of new IP-led pen platforms mentioned in previous filings. The upcoming AGM will be the next key event for shareholder approval of management re-appointments.
Shaily Q1 FY27 Standalone PAT up 46% YoY to ₹52.5 Cr; MD Re-appointed for 5 Years
Shaily Engineering Plastics reported a strong start to FY27 with standalone revenue growing 22.1% YoY to ₹274.78 Cr. Standalone Net Profit saw a significant jump of 46.1% YoY to ₹52.47 Cr, reflecting improved operational efficiencies. The Board has re-appointed Mr. Amit Mahendra Sanghvi as Managing Director for a five-year term effective October 2026, ensuring leadership continuity. Additionally, September 11, 2026, has been fixed as the record date for the final dividend of FY 2025-26.
Confidence: HIGH
What changedThe company reported its Q1 FY27 financial results, extended the Managing Director's tenure by five years, and finalized the dividend record date.
Why it mattersThe strong profit growth relative to revenue suggests margin expansion, likely driven by the high-margin healthcare segment. Leadership continuity is crucial for maintaining relationships with global MNC clients.
Standalone Revenue (Q1 FY27): ₹274.78 CrStandalone PAT (Q1 FY27): ₹52.47 CrYoY Revenue Growth: 22.1%YoY Standalone PAT Growth: 46.1%MD Re-appointment Term: 5 years
📅 Short termThe stock is likely to react positively to the strong earnings growth and margin improvement reported in the standalone results.
📈 Long termThe company's shift toward IP-led healthcare products and expansion into the Middle East provides a structural growth runway over the next 3-5 years.
⚠ Risk flags
- High customer concentration with large MNCs
- Potential regulatory delays in pharma dispatches (12-14 months)
Key Highlights
Standalone Revenue from operations increased 22.1% YoY to ₹274.78 Cr from ₹225.10 Cr.
Standalone Net Profit surged 46.1% YoY to ₹52.47 Cr compared to ₹35.91 Cr in the previous year's quarter.
MD Amit Mahendra Sanghvi re-appointed for a 5-year term from October 1, 2026, to September 30, 2031.
Fixed September 11, 2026, as the Record Date for the final dividend for FY 2025-26.
Allotted 40,155 equity shares of ₹2 each under the ESOP Plan 2019 during the quarter.
👀 What to Watch
Investors should monitor the execution of the healthcare segment's IP-led pen platforms, which are expected to drive higher margins as commercial supplies scale up.
Shaily Engineering FY26 PAT Surges 83% to ₹170 Cr; Healthcare Revenue Jumps 139%
Shaily Engineering Plastics reported a robust FY26 with consolidated revenue growing 26% to ₹991 crores and PAT rising 83% to ₹170 crores. The Healthcare segment was the primary driver, with revenue surging 139% to ₹393 crores, now contributing 40% of the total mix. While the Consumer segment saw a 9% decline due to weak global demand in home furnishings, EBITDA margins expanded significantly by 630 bps to 29.0%. The company achieved major milestones including the launch of Semaglutide pen injectors in Canada and entry into the semiconductor tray market.
Key Highlights
FY26 PAT grew 83% YoY to ₹170 crores with EBITDA margins expanding to 29.0%.
Healthcare revenue surged 139% to ₹393 crores, driven by the commercial launch of Semaglutide pen injectors.
Achieved first tentative U.S. approval for Semaglutide pens and European authorization for Teriparatide.
Diversified into semiconductor supply chain via a supply agreement with a Korean company for precision trays.
Board approved an enabling resolution to raise up to ₹500 crores to maintain capital agility for future growth.
👀 What to Watch
Investors should monitor the scaling of the high-margin Healthcare vertical and the ramp-up of the new semiconductor and electronics programs. The significant margin expansion and 35.8% ROCE indicate a successful transition toward a high-value, IP-led manufacturing platform.
Shaily Engineering Secures USFDA & Health Canada Approvals for Semaglutide Pen Injector
Shaily Engineering Plastics has announced regulatory approvals from the USFDA (Tentative), Health Canada, and India's CDSCO for its proprietary ShailyPen Neo™ device technology. This spring-driven pen injector is utilized in a generic Semaglutide injection, a high-growth GLP-1 therapy. The product has already been commercially launched in Canada as of May 2026 and has been available in India since March 2026. This milestone validates Shaily's capability in the complex, IP-restricted drug delivery systems market.
Key Highlights
Received USFDA Tentative Approval and Health Canada Notice of Compliance for generic Semaglutide combination product.
ShailyPen Neo™ platform is a rare spring-driven injector compatible with ISO-standard 3 mL and 1.5 mL fill cartridges.
Commercial launch successfully executed in Canada (May 2026) and India (March 2026).
Shaily is responsible for the full design, development, and manufacturing of the device components.
The technology addresses a highly restricted IP environment in the injectable therapies market.
👀 What to Watch
This is a significant value-unlocking event that positions Shaily as a key global supplier in the lucrative GLP-1 delivery market. Investors should monitor the conversion of USFDA Tentative Approval to Final Approval and subsequent volume ramp-up in North American markets.
Shaily Engineering to Raise ₹500 Cr, Declares ₹3 Dividend and Appoints New COO
Shaily Engineering Plastics has approved a significant fundraise of up to ₹500 Crores to fuel its transition into a diversified, IP-led global manufacturing platform. The company is expanding its footprint into high-growth sectors including consumer electronics and semiconductor components, recently signing a supply agreement with a Korean firm for semiconductor trays. Alongside these growth plans, the board recommended a final dividend of ₹3 per share (150% of face value) for FY26. To lead its core healthcare vertical, the company has appointed Mr. Chi Hung Kam, a veteran with over 20 years of experience at SHL Medical and Flextronics, as COO and Key Managerial Personnel.
Key Highlights
Approved enabling resolution to raise up to ₹500 Crores via QIP, rights issue, or private placement.
Recommended a final dividend of ₹3 per equity share (150% on face value of ₹2) for FY26.
Appointed Mr. Chi Hung Kam (Joe Kam) as COO – Healthcare and KMP, effective May 20, 2026.
Signed a strategic supply agreement with a Korean firm for the manufacture of semiconductor trays.
Pivoting business model toward IP-led manufacturing in healthcare, electronics, and semiconductors.
👀 What to Watch
Investors should monitor the execution of the new semiconductor supply agreement and the specific terms of the ₹500 Crore fundraise as it develops. The strategic shift toward higher-margin, IP-led manufacturing and the addition of top-tier global leadership are strong long-term positives.
Shaily Engineering FY26 PAT Surges 83% to ₹170 Cr; Healthcare Revenue Grows 139%
Shaily Engineering Plastics delivered a robust FY26 performance, with consolidated PAT growing 83% YoY to ₹169.9 crore and revenue increasing 26% to ₹990.7 crore. The healthcare segment was the primary growth engine, with revenue surging 139% to ₹392.8 crore, offsetting a 9% decline in the consumer segment. The company reported significant margin expansion, with EBITDA margins reaching 29% due to a favorable product mix. Additionally, the board has approved an enabling resolution to raise up to ₹500 crore to support its transition into an IP-led global manufacturing platform.
Key Highlights
Consolidated FY26 PAT increased 83% YoY to ₹169.9 crore, while EBITDA grew 61% to ₹287.7 crore.
Healthcare segment revenue jumped 139% to ₹392.8 crore, now contributing significantly to the total revenue mix.
Secured a major ₹423 crore order from a domestic pharma company for pen injectors to be supplied over four years.
Diversified into the semiconductor supply chain through an agreement with a Korean company for semiconductor trays.
Board approved an enabling resolution for raising up to ₹500 crore via QIP, preferential issue, or other modes.
👀 What to Watch
Investors should focus on the company's successful pivot toward high-margin healthcare and semiconductor segments, which is driving superior RoCE of 35.8%. The stock remains a strong play on specialized contract manufacturing, though the planned ₹500 crore fundraise may lead to equity dilution in the near term.
Shaily Engineering Plastics to Raise ₹500 Cr; Recommends ₹3 Final Dividend
Shaily Engineering Plastics has approved an enabling resolution to raise up to ₹500 Crores to fund its transition into a diversified, IP-led global manufacturing platform. The Board also recommended a final dividend of ₹3 per share (150% of face value) for the financial year ended March 31, 2026. Strategically, the company is diversifying into high-growth sectors including consumer electronics and semiconductor trays, the latter through a new agreement with a Korean firm. The appointment of Mr. Chi Hung Kam as COO - Healthcare further strengthens the leadership for its regulated business segments.
Key Highlights
Approved a significant fundraise of up to ₹500 Crores through various modes including QIP or private placement.
Recommended a final dividend of ₹3 per equity share (150% on face value of ₹2) for FY 2025-26.
Announced strategic entry into the semiconductor supply chain with a supply agreement for semiconductor trays.
Appointed Mr. Chi Hung Kam, a veteran from SHL Medical, as COO - Healthcare and Key Managerial Personnel.
Transitioning business model from precision plastics to an IP-led global manufacturing platform.
👀 What to Watch
Investors should view the ₹500 Cr fundraise and the entry into the semiconductor space as strong growth catalysts. Monitor the execution of the new supply agreements and the impact of the new leadership on the healthcare vertical's margins.
Shaily Engineering to Raise ₹500 Cr for Expansion; Declares ₹3 Final Dividend
Shaily Engineering Plastics has approved a significant fundraise of up to ₹500 Crores to transition into an IP-led global manufacturing platform. The board also recommended a final dividend of ₹3 per equity share (150% of face value) for FY26. Strategically, the company is diversifying into high-growth sectors including consumer electronics and semiconductor trays, recently signing a supply agreement with a Korean firm. To lead this growth, the company appointed Mr. Chi Hung Kam, a veteran from SHL Medical and Flextronics, as COO for Healthcare and Key Managerial Personnel.
Key Highlights
Approved enabling resolution to raise up to ₹500 Crores through QIP, rights issue, or private placement.
Recommended a final dividend of ₹3 per share (150%) on equity shares of ₹2 face value for FY 2025-26.
Appointed Mr. Chi Hung Kam (Joe Kam) as COO - Healthcare and KMP, bringing 20+ years of international manufacturing experience.
Announced strategic entry into the semiconductor supply chain via a supply agreement with a Korean firm for semiconductor trays.
Transitioning business model from precision plastics to a diversified, IP-led global manufacturing platform.
👀 What to Watch
Investors should view the ₹500 Cr fundraise and the entry into the semiconductor supply chain as strong growth catalysts. Monitor the specific terms of the fundraise and the ramp-up of the new semiconductor and healthcare automation initiatives.
Shaily Engineering Recommends ₹3 Dividend and Approves ₹500 Cr Fundraise for Strategic Expansion
Shaily Engineering Plastics has recommended a final dividend of ₹3 per share (150% of face value) for FY26. More significantly, the board approved an enabling resolution to raise up to ₹500 Crores to fund its transition into a diversified, IP-led global manufacturing platform. The company is aggressively expanding beyond healthcare into consumer electronics and has secured a strategic supply agreement with a Korean firm for semiconductor trays. The appointment of Joe Kam, a veteran from SHL Medical, as COO of Healthcare further underscores their focus on high-margin, regulated medical devices.
Key Highlights
Recommended a final dividend of ₹3 per equity share (150% on face value of ₹2) for FY 2025-26.
Approved an enabling resolution to raise up to ₹500 Crores through QIP, rights issue, or other modes to build financial flexibility.
Secured a supply agreement with a Korean firm for semiconductor trays, entering the global semiconductor supply chain.
Appointed Mr. Chi Hung Kam (Joe Kam) as COO – Healthcare and KMP, bringing 20+ years of international manufacturing experience.
Strategic pivot towards becoming an IP-led platform across drug delivery devices, consumer electronics, and semiconductor components.
👀 What to Watch
Investors should look favorably upon the ₹500 Cr fundraise as it signals a major scaling phase into high-growth sectors like semiconductors. Monitor the execution of the new supply agreements and the potential equity dilution from the upcoming fundraise.
Shaily Engineering Approves ₹500 Cr Fundraise and ₹3 Final Dividend
Shaily Engineering Plastics has approved a significant enabling resolution to raise up to ₹500 crores to fund its transition into a diversified, IP-led global manufacturing platform. The board recommended a final dividend of ₹3 per share (150% of face value) for FY26, reflecting stable returns alongside growth plans. Strategically, the company is expanding into high-growth sectors including consumer electronics and semiconductor components, highlighted by a new supply agreement with a Korean firm for semiconductor trays. The appointment of Mr. Chi Hung Kam as COO-Healthcare brings 20+ years of international experience to lead their medical device vertical.
Key Highlights
Approved an enabling resolution for a fundraise of up to ₹500 crores via QIP, rights issue, or private placement.
Recommended a final dividend of ₹3 per equity share (150% on face value of ₹2) for FY 2025-26.
Appointed Mr. Chi Hung Kam (Joe Kam), formerly of SHL Medical, as COO-Healthcare and Key Managerial Personnel.
Announced a strategic entry into the semiconductor supply chain via a supply agreement with a Korean firm for semiconductor trays.
Diversifying revenue base into consumer electronics and proprietary drug delivery devices.
👀 What to Watch
The massive fundraise and entry into the semiconductor value chain mark a significant scale-up phase for Shaily; investors should monitor the specific terms of the capital raise and the execution of the new supply agreements.
Shaily Engineering Secures Rs 423 Crore Order for Pen Injectors from Domestic Pharma Major
Shaily Engineering Plastics has signed a significant contract worth approximately Rs. 423 crores with a leading domestic pharmaceutical company. The agreement involves the manufacturing and commercial supply of pen injectors over a four-year period. This contract provides strong revenue visibility and highlights the company's growing capabilities in the high-margin healthcare and medical devices segment. The deal underscores Shaily's strategic shift towards specialized, high-precision plastic components for the pharma industry.
Key Highlights
Total contract value estimated at approximately Rs. 423 crores.
Execution and supply period scheduled over the next 4 years.
Contract awarded by a large domestic pharmaceutical company for pen injector manufacturing.
Nature of the agreement is a Manufacturing & Commercial Supply Agreement.
Strengthens the company's position in the specialized healthcare plastics vertical.
👀 What to Watch
Investors should view this as a major positive for long-term revenue growth and margin expansion. Monitor the company's execution capabilities and potential for further order wins in the healthcare segment.
Shaily Engineering Q3 PAT Jumps 48% to ₹37 Cr; Plans ₹350 Cr Abu Dhabi Healthcare Expansion
Shaily Engineering reported a strong Q3 FY26 with revenue growing 27% YoY to ₹251 crores and PAT increasing 48% to ₹37 crores. The Healthcare segment was the primary driver, growing 139% YoY and now contributing 42% of total revenue. The company announced a major ₹300-350 crore expansion in Abu Dhabi to double its pen injector capacity to 150 million units by FY28. Management also highlighted strong traction in GLP-1 drug delivery devices, securing 65-75% share among first filers in the Canadian market.
Key Highlights
Q3 FY26 PAT grew 48% YoY to ₹37 crores with EBITDA margins expanding 310 bps to 26.5%.
Healthcare revenue surged 139% YoY to ₹104 crores, driven by high demand for pen and auto-injectors.
Announced ₹300-350 crore capex for a new 75 million unit capacity facility in Abu Dhabi, operational by Q4 FY28.
Secured 2 new GLP-1 customers and 2 global pharma contracts; holds ~65-75% share of first filers in Canada.
Appointed Joe Kam (ex-SHL/Flextronics) as COO of Healthcare to lead global operations from March 2026.
👀 What to Watch
Investors should favor the company's transition into a high-margin healthcare player and the aggressive global capacity expansion. Monitor the timely commercialization of the Abu Dhabi plant and the ramp-up of GLP-1 device supplies.
Shaily Engineering Q3 PAT up 48% to ₹37.4 Cr; Healthcare segment surges 139% YoY
Shaily Engineering Plastics reported a robust Q3FY26 with consolidated revenue rising 27% YoY to ₹250.5 crore. The growth was primarily driven by the Healthcare segment, which grew 139% YoY, offsetting a 13% decline in the Consumer segment. EBITDA margins expanded significantly to 26.5%, resulting in a 48% YoY increase in PAT to ₹37.4 crore. The company also announced a strategic expansion into Abu Dhabi with a ₹300-340 crore (AED 130-150m) facility for medical devices, targeting the global GLP-1 market.
Key Highlights
Consolidated Q3 Revenue grew 27% YoY to ₹250.5 Cr, while 9M FY26 PAT surged 101% to ₹129.8 Cr.
Healthcare segment revenue jumped 139% YoY to ₹104.3 Cr in Q3, driven by new GLP-1 pen injector contracts.
EBITDA margins reached 26.5% in Q3, a 310 bps improvement, reflecting a shift toward higher-margin products.
New Abu Dhabi facility planned with AED 130-150 million investment to produce 75 million pen injectors annually.
Return on Capital Employed (RoCE) improved sharply to 38.4% from 24.4% in March 2025.
👀 What to Watch
The stock remains a strong play on the medical device outsourcing theme, specifically in the high-demand GLP-1 segment. Investors should monitor the execution of the Abu Dhabi facility and the stabilization of the consumer segment.
Shaily Engineering Q3 Net Profit Surges 96% YoY to ₹35.6 Crore
Shaily Engineering Plastics reported a robust year-on-year performance for Q3 FY26, with standalone net profit nearly doubling to ₹35.64 crore from ₹18.14 crore in the previous year. Revenue from operations grew by 25.7% YoY to ₹234.64 crore, driven by strong demand in its core segments. For the nine-month period ended December 2025, the company's profit reached ₹112.64 crore, a significant jump from ₹41.38 crore in the same period last year. Despite the strong YoY growth, net profit saw a sequential decline from ₹41.03 crore in Q2 FY26.
Key Highlights
Standalone Net Profit grew 96.5% YoY to ₹35.64 crore in Q3 FY26.
Revenue from operations increased 25.7% YoY to ₹234.64 crore compared to ₹186.59 crore.
9M FY26 Net Profit stands at ₹112.64 crore, a 172% increase over 9M FY25.
Basic EPS for the quarter rose to ₹7.75 from ₹3.95 in the corresponding quarter last year.
Company recognized an incremental liability of ₹90 lakhs towards gratuity due to New Labour Code assessments.
👀 What to Watch
Investors should take note of the massive YoY profit expansion and strong 9-month performance, though the slight QoQ dip in margins warrants monitoring. The company's growth trajectory in precision plastics remains intact.
